Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions.

BACKGROUND Nephrogenic systemic fibrosis (NSF) is an uncommon fibrotic disorder occurring after administration of linear gadolinium contrast agents in patients with severely decreased kidney function. The underlying pathogenetic mechanism of fibrosis remains to be elucidated. Transforming growth factor beta (TGF-beta), a key player in the pathogenesis of fibrotic disorders, has been found to be overexpressed in NSF skin lesions. The aim of this study is to analyze the TGF-beta-SMAD-connective tissue growth factor (CTGF) axis in NSF skin lesions compared with skin specimens from patients with systemic sclerosis, hemodialysis patients without NSF, and healthy controls. Additionally, expression of tissue inhibitor of metalloproteinase 1 (TIMP-1) and antifibrotic tumor necrosis factor alpha (TNF-alpha) were examined. STUDY DESIGN Observational study. SETTING & PARTICIPANTS Full-thickness skin biopsy specimens from fibrotic lesions or healthy skin were obtained from 10 patients with NSF, 16 patients with systemic sclerosis, 8 non-NSF hemodialysis patients, and 17 healthy participants. PREDICTOR Patient diagnosis of NSF, systemic sclerosis, non-NSF hemodialysis patients, and healthy participants, as defined using skin biopsy. OUTCOME & MEASUREMENTS Dermal messenger RNA and protein expression of profibrotic TGF-beta, SMAD2, SMAD3, SMAD4, SMAD7, CTGF, TIMP-1, antifibrotic SMAD7, and TNF-alpha were analyzed using real-time reverse transcription-polymerase chain reaction and immunohistologic examination on formalin-embedded tissue. RESULTS Dermal expression of nearly all parameters differed in hemodialysis patients compared with healthy controls. In comparison to hemodialysis patients and healthy participants, we found increased messenger RNA levels for TGF-beta, the profibrotic receptor-activated SMAD2 and SMAD3, CTGF, and TIMP-1 in NSF and systemic sclerosis lesions. Few differences between NSF and non-NSF hemodialysis patients were observed for common SMAD4, inhibitory SMAD7, and TNF-alpha. LIMITATIONS Small patient cohort. CONCLUSION Our results suggest a profibrotic imbalance in the TGF-beta-SMAD-CTGF axis in NSF skin lesions. Significantly increased dermal expression of TGF-beta and TIMP-1 in non-NSF hemodialysis patients in comparison to healthy participants emphasizes the need for a hemodialysis control group for future investigations and suggests a pre-existing profibrotic situation in the skin of hemodialysis patients.

[1]  P. Altmeyer,et al.  Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. , 2009, Journal of the American Academy of Dermatology.

[2]  T. Gambichler,et al.  Detection of clonal T cells in the circulation of patients with nephrogenic systemic fibrosis. , 2009, Archives of dermatology.

[3]  T. Gambichler,et al.  Decorin is significantly overexpressed in nephrogenic systemic fibrosis. , 2009, American journal of clinical pathology.

[4]  S. Jimenez,et al.  Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. , 2009, Arthritis and rheumatism.

[5]  T. Gambichler,et al.  Up-regulation of transforming growth factor-beta3 and extracellular matrix proteins in acquired reactive perforating collagenosis. , 2009, Journal of the American Academy of Dermatology.

[6]  Minghua Wu,et al.  Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. , 2008, The American journal of pathology.

[7]  A. Leask.  Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. , 2008, Cellular signalling.

[8]  G. Wiesmüller,et al.  C-reactive protein levels and clinical symptoms following gadolinium administration in hemodialysis patients. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  B. Kelly,et al.  Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. , 2008, Journal of the American Academy of Dermatology.

[10]  H. Lan.  Smad7 as a therapeutic agent for chronic kidney diseases. , 2008, Frontiers in bioscience : a journal and virtual library.

[11]  P. Marckmann,et al.  Nephrogenic systemic fibrosis: epidemiology update , 2008, Current opinion in nephrology and hypertension.

[12]  T. Gambichler,et al.  Differential mRNA Expression of Antimicrobial Peptides and Proteins in Atopic Dermatitis as Compared to Psoriasis Vulgaris and Healthy Skin , 2008, International Archives of Allergy and Immunology.

[13]  D. Abraham,et al.  Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. , 2008, Cytokine & growth factor reviews.

[14]  H. Ihn.  Autocrine TGF- signaling in the pathogenesis of systemic sclerosis , 2008 .

[15]  D. Fiorentino,et al.  Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. , 2007, Archives of dermatology.

[16]  P. Dijke,et al.  Transforming Growth Factor-β Receptor Type I-dependent Fibrogenic Gene Program Is Mediated via Activation of Smad1 and ERK1/2 Pathways* , 2007, Journal of Biological Chemistry.

[17]  S. Cowper,et al.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. , 2007, Journal of the American Academy of Dermatology.

[18]  B. D. Cohen.  Premature aging in uremia , 2007, Molecular and Cellular Biochemistry.

[19]  R. Bucala,et al.  Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy) , 2006, Current opinion in rheumatology.

[20]  T. Grobner.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  F. Mendoza,et al.  Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. , 2006, Seminars in arthritis and rheumatism.

[22]  R. Elenitsas,et al.  Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema , 2005, Journal of cutaneous pathology.

[23]  P. Altmeyer,et al.  Immunohistochemical investigations and introduction of new therapeutic strategies in scleromyxoedema: Case report , 2004, BMC dermatology.

[24]  S. Jimenez,et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.

[25]  Yong Li,et al.  Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. , 2004, The American journal of pathology.

[26]  R. Iozzo,et al.  The role of decorin in collagen fibrillogenesis and skin homeostasis , 2002, Glycoconjugate Journal.

[27]  J. Varga.  Scleroderma and Smads: dysfunctional Smad family dynamics culminating in fibrosis. , 2002, Arthritis and rheumatism.

[28]  P. Goldschmidt-Clermont,et al.  Deficient Smad7 expression: A putative molecular defect in scleroderma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[30]  P. Leboit,et al.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.

[31]  E. Ruoslahti,et al.  Negative regulation of transforming growth factor-β by the proteoglycan decorin , 1990, Nature.